How the Oral Biologics & Biosimilar Drugs Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Primary Drivers Are Supporting the Continued Market Growth of theOral Biologics & Biosimilar Drugs Market?
The rising incidence of chronic diseases like arthritis, asthma, and cancer is expected to drive the growth of the oral biologics and biosimilars market. Chronic diseases have become more prevalent due to factors such as long working hours and unhealthy lifestyles. The United Nations reports that by 2030, chronic diseases will account for 70% of global deaths. As chronic diseases continue to rise, so will the demand for biologics and biosimilars, propelling the growth of this market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
#What Are the Key Projections for the CAGR of the Oral Biologics & Biosimilar Drugs Market From 2025 to 2034?
The oral biologics & biosimilar drugs market size has grown rapidly in recent years. It will grow from $7.19 billion in 2024 to $8.6 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth is attributed to the rising prevalence of chronic diseases, increasing awareness of oral biologics, patent expirations, and the growing demand for biosimilars.
The oral biologics & biosimilar drugs market is set to experience rapid expansion, expected to reach $15.11 billion by 2029 with a CAGR of 15.1%. The growth is fueled by targeted therapies, a growing focus on preventive medicine, higher healthcare spending, and an aging population. Notable trends include advancements in oral delivery technology, the rise of orally administered biologics, innovations in biosimilars, and a focus on patient-centric care.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792
What Are the Key Market Innovations in theOral Biologics & Biosimilar Drugs Market Over the Coming Years?
The oral biologics and biosimilars market is seeing a rise in the creation of insulin biosimilars. Eli Lilly launched Rezvoglar, an insulin glargine biosimilar, in April 2023, which provides a cost-effective alternative for managing diabetes in various patient groups.
Who Are the Key Market Players Influencing the Growth of the Corn and Oral Biologics & Biosimilar Drugs Industry?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
Which Key Market Segments Comprise the Oral Biologics & Biosimilar Drugs Market and Drive Its Revenue Growth?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=3792&type=smp
Which Regions Are Emerging as Leaders in the Oral Biologics & Biosimilar Drugs Market?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Browse Through More Reports Similar to the Global Oral Biologics & Biosimilar Drugs Market 2025, By The Business Research Company:
Dental Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report
Dental Equipment And Supplies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-equipment-and-supplies-global-market-report
Dental Practice Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
